COMMUNIQUÉS West-GlobeNewswire

-
IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors
15/10/2018 -
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
15/10/2018 -
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
15/10/2018 -
CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™
15/10/2018 -
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15/10/2018 -
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
15/10/2018 -
GUERBET : Information sur les opération effectuées dans le cadre du programme de rachat d'actions
15/10/2018 -
PacBio Long-Read Sequencing Featured at ASHG Annual Meeting
15/10/2018 -
Retrotope Presents Data Demonstrating Arrest of Disease Progression with Treatment of RT001 in Patients with Infantile Neuroaxonal Dystrophy (INAD)
15/10/2018 -
Theratechnologies Appoints New Board Member
15/10/2018 -
Theratechnologies nomme un nouveau membre à son conseil d’administration
15/10/2018 -
Apotheca Biosciences (PCFP) Announces Addition of Dr. Mali Reddy, Seven Time Nobel Prize Nominee, as Chief Medical Adviser & Medical Researcher
15/10/2018 -
EDAP TMS SA : EDAP Announces Expiration of Tranche of Outstanding Warrants
15/10/2018 -
XORTX Announces New Clinical Advisory Board Members
15/10/2018 -
Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals
15/10/2018 -
Aravive Biologics and Versartis Complete Merger
15/10/2018 -
Loxo Oncology Announces Receipt of Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-292 for the Treatment of RET Fusion-Positive Thyroid Cancer
15/10/2018 -
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
15/10/2018 -
Tetra Bio-Pharma Names Dr. Guy Chamberland as Chief Executive Officer and Chief Scientific Officer
15/10/2018
Pages